MRK · earnings call history
Merck Q2 FY26 — Strong Oncology and New Launch Performance, Accelerated Pipeline Derisking
Read the briefMerck & Co., Inc. Q1 FY26 — Strong Oncology & Pipeline Progress
Read the briefMerck & Co., Inc. Q4 FY25 — Strong Pipeline Momentum and New Product Contributions Drive Growth
Read the briefMerck & Co., Inc. Q3 FY25 — Strong Pipeline Advancements and New Product Launches
Read the briefMerck & Co., Inc. Q2 FY25 — Strong Pipeline Momentum and Strategic Reinvestment
Read the briefMerck & Co., Inc. Q1 FY25 — Strong Pipeline Advancement and New Product Launches Drive Performance
Read the briefMerck & Co. Q4 FY24 — Strong Growth Offset by GARDASIL China Headwinds
Read the briefBrowse all US companies on the earnings-call register.